Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.

Takayama K, Furusyo N, Ogawa E, Shimizu M, Hiramine S, Mitsumoto F, Ura K, Toyoda K, Murata M, Hayashi J.

J Infect Chemother. 2014 Sep;20(9):577-81. doi: 10.1016/j.jiac.2014.06.002. Epub 2014 Jul 4.

PMID:
25000830
2.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N.

Antiviral Res. 2013 Sep;99(3):214-20. doi: 10.1016/j.antiviral.2013.05.015. Epub 2013 Jun 7.

PMID:
23747481
3.

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.

PMID:
24120953
4.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.

Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.

J Med Virol. 2014 Nov;86(11):1868-76. doi: 10.1002/jmv.24016. Epub 2014 Jul 23.

PMID:
25052594
5.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
6.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

7.

Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

PLoS One. 2013 Nov 12;8(11):e80528. doi: 10.1371/journal.pone.0080528. eCollection 2013.

8.

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.

Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F.

J Viral Hepat. 2014;21(9):e98-e107. doi: 10.1111/jvh.12237. Epub 2014 Feb 25.

PMID:
24612466
9.

Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.

Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Clin Microbiol. 2013 Sep;51(9):2862-8. doi: 10.1128/JCM.01129-13. Epub 2013 Jun 19.

10.

Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.

Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T.

Antiviral Res. 2014 May;105:112-7. doi: 10.1016/j.antiviral.2014.02.019. Epub 2014 Mar 1.

PMID:
24594347
11.

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H.

J Clin Virol. 2010 Jan;47(1):76-8. doi: 10.1016/j.jcv.2009.09.029. Epub 2009 Oct 25.

PMID:
19857995
12.

A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.

Abe H, Hayes CN, Hiraga N, Imamura M, Tsuge M, Miki D, Takahashi S, Ochi H, Chayama K.

Am J Gastroenterol. 2013 Sep;108(9):1464-72. doi: 10.1038/ajg.2013.205. Epub 2013 Jul 30.

PMID:
23896953
13.

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

Gentile I, Viola C, Borgia F, Castaldo G, Borgia G.

Curr Med Chem. 2009;16(9):1115-21. Review.

PMID:
19275615
14.

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.

Susser S, Flinders M, Reesink HW, Zeuzem S, Lawyer G, Ghys A, Van Eygen V, Witek J, De Meyer S, Sarrazin C.

Antimicrob Agents Chemother. 2015 May;59(5):2746-55. doi: 10.1128/AAC.04911-14. Epub 2015 Feb 23.

15.

[Hepatitis C virus: 25 years-old, the end?].

Pol S.

Med Sci (Paris). 2013 Nov;29(11):998-1003. doi: 10.1051/medsci/20132911016. Epub 2013 Nov 20. Review. French.

16.

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.

Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F.

Dig Liver Dis. 2015 Mar;47(3):233-41. doi: 10.1016/j.dld.2014.12.004. Epub 2014 Dec 27.

PMID:
25637450
17.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
18.

[Treatment of hepatitis C: current status and perspectives].

Pol S, Corouge M.

Rev Prat. 2014 May;64(5):605-12. French.

PMID:
24923038
19.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.

Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H.

J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16.

PMID:
23861088
20.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817

Supplemental Content

Support Center